Despite methodological rigor, many ASD RCTs exhibit limited real-world applicability and incomplete transparency Improvements in reporting over time have not translated into gains in core clinical utility. Clinicians should therefore interpret current randomized evidence in the context of patient complexity and practice variation, recognizing that many trials establish procedural efficacy under controlled conditions rather than effectiveness across heterogeneous ASD populations.
Achilova et al. (Fri,) studied this question.